{"id":516749,"date":"2021-07-22T16:12:03","date_gmt":"2021-07-22T20:12:03","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/lantern-pharma-to-host-second-quarter-2021-operating-and-financial-results-conference-call-on-thursday-july-29-2021-at-430-p-m-et\/"},"modified":"2021-07-22T16:12:03","modified_gmt":"2021-07-22T20:12:03","slug":"lantern-pharma-to-host-second-quarter-2021-operating-and-financial-results-conference-call-on-thursday-july-29-2021-at-430-p-m-et","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/lantern-pharma-to-host-second-quarter-2021-operating-and-financial-results-conference-call-on-thursday-july-29-2021-at-430-p-m-et\/","title":{"rendered":"Lantern Pharma to Host Second Quarter 2021 Operating and Financial Results Conference Call on Thursday, July 29, 2021 at 4:30 p.m. ET"},"content":{"rendered":"
\n

PR Newswire<\/p>\n<\/p><\/div>\n

\n

\n DALLAS<\/span>, July 22, 2021<\/span> \/PRNewswire\/ —\u00a0Lantern Pharma<\/b> (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR\u00ae artificial intelligence (“A.I.”) platform to improve drug discovery and development, and identify patients who will benefit from its portfolio of targeted oncology therapeutics, announced today that it will host a conference call and live webcast on Thursday, July 29, 2021<\/span> at 4:30 p.m. Eastern Time<\/span> \/ 1:30 p.m. Pacific Time<\/span> to discuss financial and operating results for the second quarter ended June 30, 2021<\/span>. The call will be led by Panna Sharma<\/span>, President and Chief Executive Officer. He will be joined on the call by other members of the management team.<\/p>\n

\n

\n
\n \"Lantern
\n <\/a>\n <\/p>\n<\/p><\/div>\n

\n Conference Call
<\/b>
\n Toll-free US and Canada<\/span>:<\/b> 800\u2013791\u20134813 \u2013 conference ID# 20284
International:<\/b>\u00a0785\u2013424\u20131102 \u2013 conference ID# 20284
Replay Number:<\/b> 1-800-839\u20135642, no passcode. Available through 11:59 pm ET<\/span> on August 29, 2021<\/span>.<\/p>\n

\n Webcast
<\/b>Live webcast will be available at: Lantern Pharma 2Q21 Earnings Call Webcast<\/a><\/p>\n

The webcast will be archived on https:\/\/ir.lanternpharma.com<\/a> through 11:59 pm ET<\/span> on August 29, 2021<\/span>.<\/p>\n

\n About Lantern Pharma
<\/b>Lantern Pharma (LTRN) is a clinical-stage oncology-focused biopharmaceutical company leveraging its proprietary RADR\u00ae <\/sup>A.I. platform and machine learning to discover biomarker signatures that identify patients most likely to respond to its pipeline of genomically-targeted therapeutics. Lantern is currently developing four drug candidates and an ADC program across seven disclosed tumor targets, including two phase 2 programs. By targeting drugs to patients whose genomic profile identifies them as having the highest probability of benefiting from the drug, Lantern’s approach represents the potential to deliver best-in-class outcomes. More information is available at: www.lanternpharma.com\u00a0and Twitter@lanternpharma<\/a>.<\/p>\n

\n Contact
<\/b>
\n Panna Sharma<\/span>, CEO
IR@lanternpharma.com<\/a>
(628)777-3339<\/p>\n

\n Forward-looking Statements
<\/b>This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements include, among other things, statements relating to: future events or our future financial performance; the potential advantages of our RADR\u00ae<\/sup>\u00a0platform in identifying drug candidates and patient populations that are likely to respond to a drug candidate; our strategic plans to advance the development of our drug candidates and antibody drug conjugate (ADC) development program; estimates regarding the development timing for our drug candidates and ADC development program; our research and development efforts of our internal drug discovery programs and the utilization of our RADR\u00ae<\/sup>\u00a0platform to streamline the drug development process; our intention to leverage artificial intelligence, machine learning and genomic data to streamline and transform the pace, risk and cost of oncology drug discovery and development and to identify patient populations that would likely respond to a drug candidate; estimates regarding potential markets and potential market sizes; sales estimates for our drug candidates and our plans to discover and develop drug candidates and to maximize their commercial potential by advancing such drug candidates ourselves or in collaboration with others. Any statements that are not statements of historical fact (including, without limitation, statements that use words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “target,” “objective,” “aim,” “should,” “will,” “would,” or the negative of these words or other similar expressions) should be considered forward-looking statements. There are a number of important factors that could cause our actual results to differ materially from those indicated by the forward-looking statements, such as (i) the impact of the COVID-19 pandemic, (ii) the risk that none of our product candidates has received FDA marketing approval, and we may not be able to successfully initiate, conduct, or conclude clinical testing for or obtain marketing approval for our product candidates, (iii) the risk that no drug product based on our proprietary RADR A.I. platform has received FDA marketing approval or otherwise been incorporated into a commercial product, and (iv) those other factors set forth in the Risk Factors section in our Annual Report on Form 10-K for the year ended\u00a0December 31, 2020, filed with the Securities and Exchange Commission on\u00a0March 10, 2021. You may access our Annual Report on Form 10-K for the year ended\u00a0December 31, 2020\u00a0under the investor SEC filings tab of our website at\u00a0www.lanternpharma.com<\/a>\u00a0or on the SEC’s website at\u00a0www.sec.gov<\/a>. Given these risks and uncertainties, we can give no assurances that our forward-looking statements will prove to be accurate, or that any other results or events projected or contemplated by our forward-looking statements will in fact occur, and we caution investors not to place undue reliance on these statements. All forward-looking statements in this press release represent our judgment as of the date hereof, and, except as otherwise required by law, we disclaim any obligation to update any forward-looking statements to conform the statement to actual results or changes in our expectations.<\/p>\n

<\/div>\n

\n \"Cision\" View original content to download multimedia:https:\/\/www.prnewswire.com\/news-releases\/lantern-pharma-to-host-second-quarter-2021-operating-and-financial-results-conference-call-on-thursday-july-29-2021-at-430-pm-et-301339870.html<\/a><\/p>\n

SOURCE Lantern Pharma<\/p>\n<\/p><\/div>\n

\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

PR Newswire DALLAS, July 22, 2021 \/PRNewswire\/ —\u00a0Lantern Pharma (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR\u00ae artificial intelligence (“A.I.”) platform to improve drug discovery and development, and identify patients who will benefit from its portfolio of targeted oncology therapeutics, announced today that it will host a conference call and live webcast on Thursday, July 29, 2021 at 4:30 p.m. Eastern Time \/ 1:30 p.m. Pacific Time to discuss financial and operating results for the second quarter ended June 30, 2021. The call will be led by Panna Sharma, President and Chief Executive Officer. He will be joined on the call by other members of the management team. Conference Call Toll-free US and Canada: 800\u2013791\u20134813 \u2013 conference … <\/p>\n

Continue reading “Lantern Pharma to Host Second Quarter 2021 Operating and Financial Results Conference Call on Thursday, July 29, 2021 at 4:30 p.m. ET”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-516749","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nLantern Pharma to Host Second Quarter 2021 Operating and Financial Results Conference Call on Thursday, July 29, 2021 at 4:30 p.m. ET - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/lantern-pharma-to-host-second-quarter-2021-operating-and-financial-results-conference-call-on-thursday-july-29-2021-at-430-p-m-et\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Lantern Pharma to Host Second Quarter 2021 Operating and Financial Results Conference Call on Thursday, July 29, 2021 at 4:30 p.m. ET - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PR Newswire DALLAS, July 22, 2021 \/PRNewswire\/ —\u00a0Lantern Pharma (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR\u00ae artificial intelligence (“A.I.”) platform to improve drug discovery and development, and identify patients who will benefit from its portfolio of targeted oncology therapeutics, announced today that it will host a conference call and live webcast on Thursday, July 29, 2021 at 4:30 p.m. Eastern Time \/ 1:30 p.m. Pacific Time to discuss financial and operating results for the second quarter ended June 30, 2021. The call will be led by Panna Sharma, President and Chief Executive Officer. He will be joined on the call by other members of the management team. Conference Call Toll-free US and Canada: 800\u2013791\u20134813 \u2013 conference … Continue reading "Lantern Pharma to Host Second Quarter 2021 Operating and Financial Results Conference Call on Thursday, July 29, 2021 at 4:30 p.m. ET"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/lantern-pharma-to-host-second-quarter-2021-operating-and-financial-results-conference-call-on-thursday-july-29-2021-at-430-p-m-et\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-07-22T20:12:03+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mma.prnewswire.com\/media\/1216507\/Lantern_Pharma_Logo.jpg\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lantern-pharma-to-host-second-quarter-2021-operating-and-financial-results-conference-call-on-thursday-july-29-2021-at-430-p-m-et\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lantern-pharma-to-host-second-quarter-2021-operating-and-financial-results-conference-call-on-thursday-july-29-2021-at-430-p-m-et\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Lantern Pharma to Host Second Quarter 2021 Operating and Financial Results Conference Call on Thursday, July 29, 2021 at 4:30 p.m. ET\",\"datePublished\":\"2021-07-22T20:12:03+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lantern-pharma-to-host-second-quarter-2021-operating-and-financial-results-conference-call-on-thursday-july-29-2021-at-430-p-m-et\\\/\"},\"wordCount\":820,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lantern-pharma-to-host-second-quarter-2021-operating-and-financial-results-conference-call-on-thursday-july-29-2021-at-430-p-m-et\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/1216507\\\/Lantern_Pharma_Logo.jpg\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lantern-pharma-to-host-second-quarter-2021-operating-and-financial-results-conference-call-on-thursday-july-29-2021-at-430-p-m-et\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lantern-pharma-to-host-second-quarter-2021-operating-and-financial-results-conference-call-on-thursday-july-29-2021-at-430-p-m-et\\\/\",\"name\":\"Lantern Pharma to Host Second Quarter 2021 Operating and Financial Results Conference Call on Thursday, July 29, 2021 at 4:30 p.m. ET - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lantern-pharma-to-host-second-quarter-2021-operating-and-financial-results-conference-call-on-thursday-july-29-2021-at-430-p-m-et\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lantern-pharma-to-host-second-quarter-2021-operating-and-financial-results-conference-call-on-thursday-july-29-2021-at-430-p-m-et\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/1216507\\\/Lantern_Pharma_Logo.jpg\",\"datePublished\":\"2021-07-22T20:12:03+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lantern-pharma-to-host-second-quarter-2021-operating-and-financial-results-conference-call-on-thursday-july-29-2021-at-430-p-m-et\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lantern-pharma-to-host-second-quarter-2021-operating-and-financial-results-conference-call-on-thursday-july-29-2021-at-430-p-m-et\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lantern-pharma-to-host-second-quarter-2021-operating-and-financial-results-conference-call-on-thursday-july-29-2021-at-430-p-m-et\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/1216507\\\/Lantern_Pharma_Logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/1216507\\\/Lantern_Pharma_Logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lantern-pharma-to-host-second-quarter-2021-operating-and-financial-results-conference-call-on-thursday-july-29-2021-at-430-p-m-et\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Lantern Pharma to Host Second Quarter 2021 Operating and Financial Results Conference Call on Thursday, July 29, 2021 at 4:30 p.m. ET\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Lantern Pharma to Host Second Quarter 2021 Operating and Financial Results Conference Call on Thursday, July 29, 2021 at 4:30 p.m. ET - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/lantern-pharma-to-host-second-quarter-2021-operating-and-financial-results-conference-call-on-thursday-july-29-2021-at-430-p-m-et\/","og_locale":"en_US","og_type":"article","og_title":"Lantern Pharma to Host Second Quarter 2021 Operating and Financial Results Conference Call on Thursday, July 29, 2021 at 4:30 p.m. ET - Market Newsdesk","og_description":"PR Newswire DALLAS, July 22, 2021 \/PRNewswire\/ —\u00a0Lantern Pharma (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR\u00ae artificial intelligence (“A.I.”) platform to improve drug discovery and development, and identify patients who will benefit from its portfolio of targeted oncology therapeutics, announced today that it will host a conference call and live webcast on Thursday, July 29, 2021 at 4:30 p.m. Eastern Time \/ 1:30 p.m. Pacific Time to discuss financial and operating results for the second quarter ended June 30, 2021. The call will be led by Panna Sharma, President and Chief Executive Officer. He will be joined on the call by other members of the management team. Conference Call Toll-free US and Canada: 800\u2013791\u20134813 \u2013 conference … Continue reading \"Lantern Pharma to Host Second Quarter 2021 Operating and Financial Results Conference Call on Thursday, July 29, 2021 at 4:30 p.m. ET\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/lantern-pharma-to-host-second-quarter-2021-operating-and-financial-results-conference-call-on-thursday-july-29-2021-at-430-p-m-et\/","og_site_name":"Market Newsdesk","article_published_time":"2021-07-22T20:12:03+00:00","og_image":[{"url":"https:\/\/mma.prnewswire.com\/media\/1216507\/Lantern_Pharma_Logo.jpg","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lantern-pharma-to-host-second-quarter-2021-operating-and-financial-results-conference-call-on-thursday-july-29-2021-at-430-p-m-et\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lantern-pharma-to-host-second-quarter-2021-operating-and-financial-results-conference-call-on-thursday-july-29-2021-at-430-p-m-et\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Lantern Pharma to Host Second Quarter 2021 Operating and Financial Results Conference Call on Thursday, July 29, 2021 at 4:30 p.m. ET","datePublished":"2021-07-22T20:12:03+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lantern-pharma-to-host-second-quarter-2021-operating-and-financial-results-conference-call-on-thursday-july-29-2021-at-430-p-m-et\/"},"wordCount":820,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lantern-pharma-to-host-second-quarter-2021-operating-and-financial-results-conference-call-on-thursday-july-29-2021-at-430-p-m-et\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/1216507\/Lantern_Pharma_Logo.jpg","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lantern-pharma-to-host-second-quarter-2021-operating-and-financial-results-conference-call-on-thursday-july-29-2021-at-430-p-m-et\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/lantern-pharma-to-host-second-quarter-2021-operating-and-financial-results-conference-call-on-thursday-july-29-2021-at-430-p-m-et\/","name":"Lantern Pharma to Host Second Quarter 2021 Operating and Financial Results Conference Call on Thursday, July 29, 2021 at 4:30 p.m. ET - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lantern-pharma-to-host-second-quarter-2021-operating-and-financial-results-conference-call-on-thursday-july-29-2021-at-430-p-m-et\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lantern-pharma-to-host-second-quarter-2021-operating-and-financial-results-conference-call-on-thursday-july-29-2021-at-430-p-m-et\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/1216507\/Lantern_Pharma_Logo.jpg","datePublished":"2021-07-22T20:12:03+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lantern-pharma-to-host-second-quarter-2021-operating-and-financial-results-conference-call-on-thursday-july-29-2021-at-430-p-m-et\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/lantern-pharma-to-host-second-quarter-2021-operating-and-financial-results-conference-call-on-thursday-july-29-2021-at-430-p-m-et\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lantern-pharma-to-host-second-quarter-2021-operating-and-financial-results-conference-call-on-thursday-july-29-2021-at-430-p-m-et\/#primaryimage","url":"https:\/\/mma.prnewswire.com\/media\/1216507\/Lantern_Pharma_Logo.jpg","contentUrl":"https:\/\/mma.prnewswire.com\/media\/1216507\/Lantern_Pharma_Logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lantern-pharma-to-host-second-quarter-2021-operating-and-financial-results-conference-call-on-thursday-july-29-2021-at-430-p-m-et\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Lantern Pharma to Host Second Quarter 2021 Operating and Financial Results Conference Call on Thursday, July 29, 2021 at 4:30 p.m. ET"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/516749","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=516749"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/516749\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=516749"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=516749"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=516749"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}